1. Anti-complement 5 antibody ameliorates antibody-mediated rejection after liver transplantation in rats
- Author
-
Tetsuya Tajima, Koichiro Hata, Jiro Kusakabe, Hidetaka Miyauchi, Joshua Sam Badshah, Shoichi Kageyama, Xiangdong Zhao, Sung-Kwon Kim, Tatsuaki Tsuruyama, Varvara A. Kirchner, Takeshi Watanabe, Shinji Uemoto, and Etsuro Hatano
- Subjects
antibody-mediated rejection (AMR) ,liver transplantation ,complement 5 ,eculizumab ,donor-specific antibody (DSA) ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Antibody-mediated rejection (AMR) remains a refractory rejection after donor-specific antibody (DSA)-positive or blood-type incompatible liver transplantation (LT), even in the era of pre-transplant rituximab desensitization. This is due to the lack of not only effective post-transplant treatments but also robust animal models to develop/validate new interventions. Orthotopic LT from male Dark Agouti (DA) to male Lewis (LEW) rats was used to develop a rat LT-AMR model. LEW were pre-sensitized by a preceding skin transplantation from DA 4–6 weeks before LT (Group-PS), while sham procedure was performed in non-sensitized controls (Group-NS). Tacrolimus was daily administered until post-transplant day (PTD)-7 or sacrifice to suppress cellular rejections. Using this model, we validated the efficacy of anti-C5 antibody (Anti-C5) for LT-AMR. Group-PS+Anti-C5 received Anti-C5 intravenously on PTD-0 and -3. Group-PS showed increased anti-donor (DA) antibody-titers (P
- Published
- 2023
- Full Text
- View/download PDF